ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0318

Development and Validation of Algorithms to Identify Cutaneous Lupus Patients Using Diagnostic Codes and Prescription Data

Lisa Guo1, Jordan Said2, Vinod Nambudiri3 and Joseph Merola3, 1Brigham and Women's Hospital, Boston, MA, 2Harvard Medical School, Boston, MA, 3Harvard Medical School, Brigham and Women's Hospital, Boston, MA

Meeting: ACR Convergence 2022

Keywords: Administrative Data, Cutaneous, skin, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster I: Diagnosis

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: There is a paucity of epidemiological studies of cutaneous lupus erythematosus (CLE), which may be due in part to the lack of well-validated methods to identify CLE cases within large datasets such as claims databases. The purpose of this study was to develop and validate the performance of novel algorithms consisting of diagnostic codes and prescription data to identify individuals with CLE.

Methods: We identified potential study patients by querying the Mass General Brigham hospital network’s clinical data repository. We selected patients with at least one International Classification of Diseases (ICD)-10 code for cutaneous lupus, including L93.0 (discoid lupus erythematosus), L93.1 (subacute lupus erythematosus) and L93.2 (other local lupus erythematosus) from January 2016 to April 2021. Of the 1902 unique patients identified, we randomly selected a sample of 300 patients to comprise the testing cohort. We developed 12 validation algorithms to test (Table 1) based on prior studies of comparable inflammatory diseases such as systemic lupus or psoriasis. These algorithms consisted of various permutations of lupus-relevant ICD-10 codes, prescriptions for disease-specific medications (such as antimalarials) and the specialty of the coding provider. We created subsets of patients who met the criteria stipulated by each potential algorithm and determined whether each patient truly had CLE based on manual chart review of the electronic medical record. We defined a “true” case of CLE as a patient with documentation of a CLE diagnosis by a dermatologist or a rheumatologist. Positive predictive values (PPVs) were then developed for each proposed algorithm, with p-values calculated using one-sample proportion tests.

Results: Characteristics of the 300 study patients are listed in Table 2. The most common CLE ICD-10 code was L93.0. PPVs per algorithm ranged from 54.14% to 90.68% (Table 3). Algorithms that included an ICD-10 code for CLE from a dermatologist had the highest PPVs. The greater the number of ICD-10 codes for CLE, the higher the PPV, though marginally so. Including prior antimalarial prescriptions also boosted PPV.

Conclusion: We found that algorithms with at least 1 ICD-10 code for CLE from a dermatologist offered acceptable PPV. In particular, the two algorithms with the highest PPVs were 1) at least 3 CLE codes with one from a dermatologist and 2) prior antimalarial prescription with a CLE code from a dermatologist. Validated algorithms that accurately identify CLE cases will allow for further study of CLE patients using electronic medical records, claims data and large real-world databases.

Supporting image 1

Table 1. Algorithms for identifying patients with cutaneous lupus erythematosus (CLE)

Supporting image 2

Table 2. Characteristics of patients

Supporting image 3

Table 3. Positive predictive values (PPV) of potential algorithms


Disclosures: L. Guo, None; J. Said, None; V. Nambudiri, Imaging Endpoints, McGraw-Hill; J. Merola, AbbVie, Biogen, BMS, Dermavant, Eli Lilly, Janssen, Novartis, Pfizer, Sun Pharma, UCB Pharma, Arena, Avotres, EMD, LEO Pharma, Merck, Regeneron, Sanofi.

To cite this abstract in AMA style:

Guo L, Said J, Nambudiri V, Merola J. Development and Validation of Algorithms to Identify Cutaneous Lupus Patients Using Diagnostic Codes and Prescription Data [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/development-and-validation-of-algorithms-to-identify-cutaneous-lupus-patients-using-diagnostic-codes-and-prescription-data/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-and-validation-of-algorithms-to-identify-cutaneous-lupus-patients-using-diagnostic-codes-and-prescription-data/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology